Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 8, 2017
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides funding to advance diverse pipelineInitiated, with Roche, the global Phase 2 PASADENA st...
Aug 15, 2017
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Irelan...
Sep 18, 2017
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP ProductionClinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related Quality of LifeData Presented at Heart Failure Society of...
Sep 28, 2017
Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a single ascending dose (SAD) studyObserved clinical efficacy...
Oct 31, 2017
DUBLIN, Ireland, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quarter and first nine months of 2017 on November 7,...
Nov 1, 2017
DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Cre...
Nov 7, 2017
Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017; quarter-end cash and restricted cash position of $460.1 million, provides funding to advance diverse pipelinePresented new research at HFSA Annual Scientific Meet...
Nov 16, 2017
Clinical development programs advancing toward key milestonesDr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNPNovel discovery pipeline in neuroscience and orphan disease areas; highlights include tau and ALECT2...
Nov 22, 2017
DUBLIN, Ireland, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan arenas, today announced that members of its senior management team will present an...
Page: First Previous
...
 
= add release to Briefcase